Edwards Lifesciences (Irvine, California) reported today that it has received conditional investigational device exemption approval from the FDA to initiate a clinical trial of its Sapien 3 transcatheter aortic heart valve and accessories. The news came as a surprise to those in the industry who follow the TAVI space because Edwards had not previously discussed its plans for bringing Sapien 3 to the U.S.
Read More
